Market Research Logo

Biosimilars: Global Market, Trends and Competitor Analysis


Attention: There is an updated edition available for this report.

Biosimilars: Global Market, Trends and Competitor Analysis

Biosimilars: Global Market, Trends, and Competitor Analysis is a detailed analysis both of the market for biosimilars and for the market effects on pharmaceutical markets. The report provides a complete picture of the biosimilars market, including information on the world, United States, EU, Germany, France, UK, Italy Spain, rest of Europe, Russia, Japan, India, China, South Korea, Australia, Brazil, Mexico, Turkey, Iran, Canada and rest of world biosimilars market to 2022.

The report looks at the biosimilar market by application, including the autoimmune disease, blood disorder, cancer, diabetes and growth hormone deficiency biosimilar markets from 2006 to 2022. Biosimilars: Global Market, Trends, and Competitor Analysis also breaks down the biosimilars market by product type, including the following segments: biosimilar recombinant non-glycosylated protein market; biosimilar recombinant glycosylated protein market; monoclonal antibodies: biosimilar product sales; and biosimilar recombinant peptide and other product market from 2017 to 2022.

Biosimilars: Global Market, Trends, and Competitor Analysis provides a complete competitor analysis for 2017, by percentage of global market share. Eli Lilly, Pfizer and Sandoz are among the companies participating in this unique market and are profiled in the report.

The report draws six main market conclusions that involve patent protection, pricing, market participants, emerging markets, evolving market strategies and education.


  • Executive Summary
    • Overview
    • Scope and Methodology
    • Size and Growth of the Market
      • The World Market for Biosimilars
        • Table Global Biosimilar Market Opportunity, 2006-2022 ($ Millions)
        • Table Global Biosimilar Market Opportunity, 2006-2022 ($ Millions)
      • Trends Affecting the Market
      • Market Outlook
  • Introduction and Overview
    • Biosimilars Overview
      • Table Scientific Differences of Pharmaceuticals and Biopharmaceuticals
    • Biopharmaceutical Industry and Approval Process
    • Genetic Engineering
    • Patent Approval
    • Regulations for Biopharmaceuticals
    • History of the Prescription Generic Pharmaceuticals Industry
    • History of the Generic Approval Process
    • Regulation of Prescription Generic Pharmaceuticals
    • Biopharmaceuticals
      • Areas of Treatment for Biopharmaceuticals
  • Biosimilar Pharmaceuticals for Expired Biologic Patents
    • Table Select Marketed Biologics with Expired Patents
  • Biosimilar Pharmaceuticals for Future Expired Biologic Patents
    • Table Select Marketed Biologics with Active Patents
  • Biosimilar Pharmaceutical Regional Analysis
    • Biosimilar Market by Region
      • Table Biosimilar Market Opportunity by Broad Region, 2006-2022 ($ Millions)
      • Table Biosimilar Market Opportunity by Broad Region, 2006-2022 ($ Millions)
    • Europe and Biosimilars
      • Table Biosimilars Approved in EU
      • Table European Market for Biosimilars, 2006-2022 ($ Millions)
      • Table European Market for Biosimilars, 2006-2022 ($ Millions)
      • Table European Market for Biosimilars, Market Share by Country, 2017
      • Germany
        • Table Germany Biosimilar Market, 2017-2022 ($ millions)
      • France, Italy, Spain and United Kingdom
        • Table France Biosimilar Market, 2017-2022 ($ millions)
        • Table Italy Biosimilar Market, 2017-2022 ($ millions)
        • Table United Kingdom Biosimilar Market, 2017-2022 ($ millions)
        • Table Spain Biosimilar Market, 2017-2022 ($ millions)
      • Russia
        • Table Russia Biosimilar Market, 2017-2022 ($ millions)
    • United States and Biosimilars
      • Table Biosimilars Approved in United States
      • Table United States Market for Biosimilars, 2015-2022 ($ Millions)
      • Table United States Market for Biosimilars, 2015-2022 ($ Millions)
    • Rest of World and Biosimilars
      • Table Rest of World Market for Biosimilars, 2006-2022 ($ Millions)
      • Table Rest of World Market for Biosimilars, 2006-2022 ($ Millions)
      • Table Rest of World Market for Biosimilars, Market Share by Country, 2017
      • Japan
        • Table Biosimilars Approved in Japan
        • Table Japan Biosimilar Market, 2017-2022 ($ millions)
      • India
        • Table Biosimilars Approved in India
        • Table India Biosimilar Market, 2017-2022 ($ millions)
      • China
        • Table China Biosimilar Market, 2017-2022 ($ millions)
      • South Korea
        • Table Biosimilars Approved in South Korea
        • Table South Korea Biosimilar Market, 2017-2022 ($ millions)
      • Australia
        • Table Biosimilars Approved in Australia
        • Table Australia Biosimilar Market, 2017-2022 ($ millions)
      • Brazil
        • Table Brazil Biosimilar Market, 2017-2022 ($ millions)
      • Mexico
        • Table Mexico Biosimilar Market, 2017-2022 ($ millions)
      • Turkey
        • Table Turkey Biosimilar Market, 2017-2022 ($ millions)
      • Iran
        • Table Iran Biosimilar Market, 2017-2022 ($ millions)
      • Canada
        • Table Canada Biosimilar Market, 2017-2022 ($ millions)
  • Issues and Trends
    • Overview
      • Interchangeability
      • Patent Issues
      • Pricing Issues
        • Table Estimated Treatment Cost Per Patient of Selected Biopharmaceuticals (before patent expiration)
      • Barriers to Entry
      • Biosimilar Development
        • Table Biosimilars in Development
      • Provider Education
      • Innovator Strategies and Challenges
      • Bulk Suppliers and Contract Manufacturing
      • Bioequivalence Issues
      • International Issues
      • Reimbursement Issues
  • Market Summary
    • Total Market Size and Forecast
      • Biosimilar Market by Product Type
        • Table Biosimilar Market Value by Product Type (non-glycosylated, glycosylated and peptides/others), 2006 - 2022 ($ millions)
        • Table Biosimilar Market Value by Product Type (non-glycosylated, glycosylated and peptides/others), 2006 - 2022 ($ millions)
        • Table Biosimilar Recombinant Non-Glycosylated Protein Market, 2017-2022 ($ millions)
        • Table Recombinant Non-Glycosylated Protein Market: Biosimilar vs. Originator Market Share, 2017 vs. 2022 (%)
        • Table Insulin Originator Products vs. Biosimilar Products 2006 - 2022
        • Table Somatropin Originator Products vs. Biosimilar Products 2006 - 2022
        • Table Filgrastim Originator Products vs. Biosimilar Products 2006 - 2022
        • Table Interferon Originator Products vs. Biosimilar Products 2006 - 2022
        • Table Biosimilar Recombinant Glycosylated Protein Market, 2017-2022 ($ millions)
        • Table Recombinant Glycosylated Protein Market: Biosimilar vs. Originator Market Share, 2017 vs. 2022 (%)
        • Table Erythropoietin Originator Products vs. Biosimilar Products 2006 - 2022
        • Table Monoclonal Antibodies Originator Products vs. Biosimilar Products 2006 - 2022
        • Table Monoclonal Antibodies: Biosimilar Product Sales 2017 vs. 2022
        • Table Follitropin Originator Products vs. Biosimilar Products 2006 - 2022
        • Table Biosimilar Recombinant Peptide and Other Product Market, 2017-2022 ($ millions)
        • Table Recombinant Peptide and Other Market: Biosimilar vs. Originator Market Share, 2017 vs. 2022 (%)
        • Table Etanercept Originator Products vs. Biosimilar Products 2006 - 2022
        • Table Teriparatide Originator Products vs. Biosimilar Products 2006 - 2022
      • Biosimilar Market by Application
        • Table Autoimmune Disease Biosimilar Market 2006-2022 ($ Millions)
        • Table Blood Disorder Biosimilar Market 2006-2022 ($ Millions)
        • Table Cancer Biosimilar Market 2006-2022 ($ Millions)
        • Table Growth Hormone Deficiency Biosimilar Market 2006-2022 ($ Millions)
        • Table Diabetes Biosimilar Market 2006-2022 ($ Millions)
      • Competitor Analysis
        • Table Biosimilar Competitor Analysis, 2017
  • Conclusions
    • Several blockbuster biologics are losing patent protection
    • Cost and discount pricing
    • New market participants
    • Different strategies for emerging markets
    • Evolving biosimilar strategies
    • Education key to success of biosimilars
  • Company Profiles
    • 3SBio, Inc
      • Table 3SBio Corporate Summary
      • Company Overview
      • Company Financials
        • Table 3SBio (2014-2017) ($ millions)
    • Amega Biotech
      • Table Amega Biotech Corporate Summary
      • Company Overview
    • Amgen Biosimilars
      • Table Amgen Biosimilars Corporate Summary
      • Company Overview
      • Company Financials
        • Table Amgen (2014-2017) ($ millions)
    • Apotex, Inc.
      • Table Apotex Corporate Summary
      • Company Overview
    • AXXO GmbH
      • Table Axxo Corporate Summary
      • Company Overview
    • Beijing Four Rings Biopharmaceutical Co Ltd.
      • Table Beijing Four Rings Biopharmaceutical Corporate Summary
      • Company Overview
    • Biocad
      • Table Biocad Corporate Summary
      • Company Overview
    • Biocon Ltd
      • Table Biocon Corporate Summary
      • Company Overview
      • Company Financials
        • Table Biocon (2014-2017) ($ millions)
    • Biogen Inc.
      • Table Biogen Corporate Summary
      • Company Overview
      • Company Financials
        • Table Biogen (2014-2017) ($ millions)
    • BioGenomics Ltd.
      • Table BioGenomics Corporate Summary
      • Company Overview
    • BioPartners GmbH
      • Table BioPartners Corporate Summary
      • Company Overview
    • Biosidus S.A.
      • Table Biosidus Corporate Summary
      • Company Overview
    • Bioviz Technologies Pvt. Ltd
      • Table Bioviz Technologies Corporate Summary
      • Company Overview
    • BioXpress Therapeutics S.A.
      • Table BioXpress Therapeutics Corporate Summary
      • Company Overview
    • Boehringer Ingelheim GmbH
      • Table Boehringer Ingelheim Corporate Summary
      • Company Overview
      • Company Financials
        • Table Boehringer Ingelheim (2014-2017) ($ millions)
    • Celltrion, Inc.
      • Table Celltrion Corporate Summary
      • Company Overview
    • Chemo Group (Grupo Isud)
      • Table Chemo Group Corporate Summary
      • Company Overview
    • Coherus BioSciences, Inc
      • Table Coherus Biosciences Corporate Summary
      • Company Overview
      • Company Financials
        • Table Coherus (2014-2017) ($ thousands)
    • DM Bio (Dong-A Pharmaceuticals)
      • Table Dong- A Pharmaceuticals Corporate Summary
      • Company Overview
    • Dr. Reddy's Laboratories Limited
      • Table Dr Reddy's Laboratories Corporate Summary
      • Company Overview
      • Company Financials
        • Table Dr Reddy's Laboratories (2014-2017) ($ millions)
    • Gedeon Richter
      • Table Gedeon Richter Corporate Summary
      • Company Overview
      • Company Financials
        • Table Gedeon Richter (2014-2017) ($ millions)
    • Harvest Moon Pharmaceuticals USA, Inc.
      • Table Harvest Moon Pharmaceuticals Corporate Summary
      • Company Overview
    • Hospira, Inc.
      • Table Hospira Corporate Summary
      • Company Overview
    • Inbiopro Solutions Pvt Ltd
      • Table Inbiopro Solutions Corporate Summary
      • Company Overview
    • Intas Pharmaceuticals Ltd
      • Table Intas Pharmaceuticals Corporate Summary
      • Company Overview
      • Company Financials
        • Table Intas Pharmaceuticals (2014-2017) ($ thousands)
    • Kyowa Hakko Kirin Co, Ltd
      • Table Kyowa Hakko Kirin Corporate Summary
      • Company Overview
      • Company Financials
        • Table Kyowa Hakko Kirin (2014-2017) ($ billions)
    • LG Chem Ltd.
      • Table LG Chem Corporate Summary
      • Company Overview
    • Merck & Company
      • Table Merck Corporate Summary
      • Company Overview
      • Company Financials
        • Table Merck (2014-2017) ($ millions)
    • Momenta Pharmaceuticals Inc.
      • Table Momenta Pharmaceuticals Corporate Summary
      • Company Overview
      • Company Financials
        • Table Momenta (2014-2017) ($ thousands)
    • Mylan N.V.
      • Table Mylan Corporate Summary
      • Company Overview
      • Company Financials
        • Table Mylan (2014-2017) ($ millions)
    • PFEnex Inc.
      • Table PFEnex Corporate Summary
      • Company Overview
      • Company Financials
        • Table PFEnex (2014-2017) ($ thousands)
    • Pfizer Biosimilars Inc.
      • Table Pfizer Biosimilars Corporate Summary
      • Company Overview
      • Company Financials
        • Table Pfizer (2014-2017) ($ millions)
    • Reliance GeneMedix Limited
      • Table Reliance Genemedix Corporate Summary
      • Company Overview
    • Reliance Life Sciences
      • Table Reliance Life Sciences Corporate Summary
      • Company Overview
    • Samsung Bioepis Co Ltd
      • Table Samsung Bioepis Corporate Summary
      • Company Overview
    • Sandoz International GmbH
      • Table Sandoz International Corporate Summary
      • Company Overview
      • Company Financials
        • Table Sandoz (2014-2017) ($ millions)
    • SciGen Ltd (Bioton)
      • Table SciGen Corporate Summary
      • Company Overview
      • Company Financials
        • Table SciGen (2014-2017) ($ millions)
    • Stada Arzneimittel AG
      • Table Stada Corporate Summary
      • Company Overview
      • Company Financials
        • Table Stada (2014-2017) ($ millions)
    • Teva Pharmaceutical Industries Ltd
      • Table Teva Corporate Summary
      • Company Overview
      • Company Financials
        • Table Teva (2014-2017) ($ millions)
    • Zydus Cadila Healthcare Ltd.
      • Table Zydus Cadila Corporate Summary
      • Company Overview
      • Company Financials
        • Table Zydus Cadila (2014-2017) ($ millions)

Download our eBook: How to Succeed Using Market Research

Learn how to effectively navigate the market research process to help guide your organization on the journey to success.

Download eBook

Share this report